Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia (WP5105)

Homo sapiens

Dyslipidemia is a change (either increase or decrease) of adipose levels within the blood. When there is a significant increase of this, the term hyperlipidemia is used. With a significant decrease, we talk about hypolipoproteinemia. Both hyperlipidemia and hypolipoproteinemia can be classified as either acquired or familial. Familial hyperlipidemia can be classified in five types according to the Fredrickson classification.For this classification see Quispe et al. 2019 Lipodystrophy is a change (either increase or decrease) of adipose levels within the lipid tissue deposits. Lipodystrophy is classified based on wether the disease is acquired or congenital, but also wether it is geralized (through the entire body) or partial (in specific parts of the body). This classification was based on the following information by Akinci et al. []
last edited


Ulas Babayigit and Friederike Ehrhart

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens


Rare Diseases


Disease Ontology: familial partial lipodystrophy type 2 congenital generalized lipodystrophy type 1 lipid metabolism disorder hyperlipoproteinemia type IV congenital generalized lipodystrophy type 4 congenital generalized lipodystrophy type 3 familial chylomicronemia syndrome lipodystrophy familial combined hyperlipidemia familial hyperlipidemia hypolipoproteinemia familial partial lipodystrophy type 6 familial partial lipodystrophy type 1 hyperlipoproteinemia type V familial partial lipodystrophy type 4 familial hypercholesterolemia hyperlipoproteinemia type III congenital generalized lipodystrophy type 2 familial partial lipodystrophy type 5 acquired generalized lipodystrophy familial partial lipodystrophy type 3

Pathway Ontology: disease pathway


Label Type Compact Identifier Comment


  1. Acquired hyperlipidemia (secondary dyslipoproteinemias). Chait A, Brunzell JD. Endocrinol Metab Clin North Am. 1990 Jun;19(2):259–78. PubMed Europe PMC Scholia
  2. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. Garg A. J Clin Endocrinol Metab. 2011 Nov;96(11):3313–25. PubMed Europe PMC Scholia
  3. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. J Clin Endocrinol Metab. 2012 Sep;97(9):2969–89. PubMed Europe PMC Scholia
  4. Hypobetalipoproteinemia and abetalipoproteinemia. Welty FK. Curr Opin Lipidol. 2014 Jun;25(3):161–8. PubMed Europe PMC Scholia
  5. Lipodystrophy Syndromes: Presentation and Treatment. Akinci B, Sahinoz M, Oral E. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA):, Inc.; 2018. PubMed Europe PMC Scholia
  6. Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. Geller AS, Polisecki EY, Diffenderfer MR, Asztalos BF, Karathanasis SK, Hegele RA, et al. J Lipid Res. 2018 Dec;59(12):2421–35. PubMed Europe PMC Scholia
  7. Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7. Quispe R, Hendrani AD, Baradaran-Noveiry B, Martin SS, Brown E, Kulkarni KR, et al. Arch Med Sci. 2019 Sep;15(5):1195–202. PubMed Europe PMC Scholia